Tenofovir Abacavir Platelet Activation Study
NCT02093585
·
clinicaltrials.gov ↗
PHASE4
Phase
COMPLETED
Status
43
Enrollment
OTHER
Sponsor class
Conditions
HIV
Interventions
DRUG:
abacavir (600 mg QD)
DRUG:
tenofovir (245 mg QD)
Sponsor
Jan Gerstoft